Skip to main content

3 Result(s)

within Darcy V. Spicer Remove this filter Pharmacology/Toxicology Remove this filter

and

  1. No Access

    Article

    Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks

    Purpose: To identify a recommended phase II dose for the second generation glycinamide ribonucleotide transformylase (GARFT) inhibitor, AG2034, administered by intravenous bolus every 3 weeks without folate supp...

    John D. Roberts, Stephen Shibata, Darcy V. Spicer… in Cancer Chemotherapy and Pharmacology (2000)

  2. No Access

    Article

    Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation

    Purpose: Lometrexol [(6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate] is the prototype folate antimetabolite that targets the de novo purine synthesis pathway. Early phase I trials were confounded by cumulative myelo...

    John D. Roberts, Elizabeth A. Poplin… in Cancer Chemotherapy and Pharmacology (2000)

  3. No Access

    Chapter

    Oral Contraceptives and Cancer

    Combination-type oral contraceptives (COCs) reduce the risk of endometrial cancer and ovarian cancer, but increase the risk of liver cancer, and may increase the risk of breast cancer and cervical cancer. Anal...

    Malcolm C. Pike, Darcy V. Spicer in Contraception (1993)